A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Completed · Phase 1 · Has a placebo group
Conditions studied: Type 2 Diabetes
In brief
This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.
Key facts
- Study ID
- NCT00952198
- Run by
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- People needed
- 128
- Starts
- 2009-08-01
- Expected to finish
- 2010-08-01
- Last updated by the study team
- 2020-10-06
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Profil Institute for Clinical Research — Chula Vista, California, United States
- Cetero — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.